Vertex Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About VRTX

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. 

CEO
Reshma Kewalramani
CEOReshma Kewalramani
Employees
6,100
Employees6,100
Headquarters
Boston, Massachusetts
HeadquartersBoston, Massachusetts
Founded
1989
Founded1989
Employees
6,100
Employees6,100

VRTX Key Statistics

Market cap
108.23B
Market cap108.23B
Price-Earnings ratio
30.03
Price-Earnings ratio30.03
Dividend yield
Dividend yield
Average volume
1.26M
Average volume1.26M
High today
$422.54
High today$422.54
Low today
$417.39
Low today$417.39
Open price
$418.00
Open price$418.00
Volume
749.76K
Volume749.76K
52 Week high
$519.88
52 Week high$519.88
52 Week low
$362.50
52 Week low$362.50

VRTX News

TipRanks 20h
Vertex Pharmaceuticals Advances Pain Management with Suzetrigine Study

Vertex Pharmaceuticals Inc. ((VRTX)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium...

TipRanks 20h
Vertex Pharmaceuticals Advances VX-407 Study for ADPKD

Vertex Pharmaceuticals Inc. ((VRTX)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium...

TipRanks 20h
Vertex Pharmaceuticals’ VX-993 Study: A Potential Game-Changer for Diabetic Neuropathy

Vertex Pharmaceuticals Inc. ((VRTX)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium...

Analyst ratings

60%

of 35 ratings
Buy
60%
Hold
34.3%
Sell
5.7%

More VRTX News

TipRanks 21h
Vertex Pharmaceuticals’ Inaxaplin Study: A Potential Game-Changer in Kidney Disease Treatment

Vertex Pharmaceuticals Inc. ((VRTX)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium...

TipRanks 21h
Vertex and Moderna’s VX-522 Study: A Potential Breakthrough in Cystic Fibrosis Treatment

Vertex Pharmaceuticals Inc. ((VRTX)), Moderna ((MRNA)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of...

TipRanks 23h
Vertex Pharmaceuticals: Pioneering New Treatments for Kidney Disorder

Vertex Pharmaceuticals Inc. ((VRTX)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at...

TipRanks 24h
Vertex Pharmaceuticals Advances VX-670 Study for Myotonic Dystrophy Type I

Vertex Pharmaceuticals Inc. ((VRTX)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium...

TipRanks 1d
Vertex Pharmaceuticals’ VX-407 Study: A Potential Game-Changer in Oral Contraceptive Pharmacokinetics

Vertex Pharmaceuticals Inc. ((VRTX)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium...

TipRanks 1d
Vertex Pharmaceuticals Advances Cystic Fibrosis Treatment with New Pediatric Study

Vertex Pharmaceuticals Inc. ((VRTX)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium...

TipRanks 1d
Vertex Pharmaceuticals: Strong Buy Rating Backed by Promising Growth and Robust Pipeline

Vertex Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst on October 24. Analyst Evan Seigerman from BMO Capital maintained...

People also own

Based on the portfolios of people who own VRTX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.